A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant @entity263 in XXXX on @entity3457 .

@entity1 @entity263 @entity5 @entity1412 @entity3457
BACKGROUND: In @entity3457 ( @entity3457 ) @entity1 : (i) To compare the ability of a multiparametric MRI (mpMRI)-ultrasound biopsy system to detect clinically significant (CS) @entity263 with systematic 12-core biopsy (R-TRUSBx), and (ii) To assess the predictive value of mpMRI with biopsy as the reference standard. METHODS: Seventy-two @entity1 on @entity3457 prospectively underwent 3T mpMRI . MRI-ultrasound fusion biopsy (UroNavBx) and R-TRUSBx was performed. @entity5 was defined using two thresholds: 1) @entity1412   >=    7 (CS7) and 2) @entity1412   =   6 with >50% involvement (GS6). @entity5 detection rates and predictive values were determined. RESULTS: CS7 @entity5 were found in 19/72 (26%), 7 (37%) identified by UroNavBx alone, 2 (11%) by R-TRUSBx alone (P   =   0.182). UroNav targeted biopsy was 6.3  more likely to yield a core positive for CS7 @entity5 compared with R-TRUSBx (25% of 141 versus 4% of 874, P   <   0.001). Upgrading of @entity1412 occurred in 15/72 @entity1 (21%), 13 (87%) detected by UroNavBx and 10 (67%) by R-TRUSBx. The NPV of mpMRI for CS7 @entity5 was 100%. MRI suspicion level significantly predicted @entity5 on multivariate analysis (OR 3.6, P   <   0.001). CONCLUSION: UroNavBx detected @entity5 with far fewer cores compared with R-TRUSBx, and mpMRI had a perfect negative predictive value in this population. J. Magn. Reson. Imaging 2014.    2014 Wiley Periodicals, Inc.
